生物活性

• 描述Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02718066	Melanoma Rena... more >>l Cell Carcinoma Non-Small Cell Lung Cancer Collapse <<	Phase 1 Phase 2	Recruiting	January 2020	United States, Arizona ... more >> [Site 02] Mayo Clinic Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Thai Ho          United States, California [Site 11] University of California, San Diego Medical Center Recruiting La Jolla, California, United States, 92037 Contact: Lyudmila Bazhenova          United States, Florida [Site 01] Hematology - Oncology Associates of the Treasure Coast Recruiting Port Saint Lucie, Florida, United States, 34952 Contact: Heather Yeckes-Rodin          [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc. Recruiting Tampa, Florida, United States, 33612 Contact: Nikhil Khushalani          United States, Maryland [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute Recruiting Frederick, Maryland, United States, 21702 Contact: Elhamy Eskander          United States, Texas [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics Recruiting Houston, Texas, United States, 77030 Contact: Siqing Fu Collapse <<
  NCT03574402	Carcinoma, Non-Small-Cell Lung	Phase 2	Not yet recruiting	December 30, 2024	-
  NCT02697552	Non-Hodgkin's Lymphoma	Phase 1	Completed	-	Japan ... more >> Nagoya City University Hospital Aichi, Japan Fukuoka University Hospital Fukuoka, Japan NHO Kyushu Cancer Center Fukuoka, Japan Kagoshima University Medical and Dental Hospital Kagoshima, Japan Tokai University Hospital Kanagawa, Japan NHO Kumamoto Medical Center Kumamoto, Japan NHO Nagasaki Medical Center Nagasaki, Japan National Cancer Center Hospital Tokyo, Japan Collapse <<

• 更多